Will This Nasdaq Biotech Company Gain Global Recognition In The Near Future? Start Preparing Now
Full Report Arrives 9:30AM EST Tomorrow
Sign Up To My SMS Update System - Directions Below
It's already night time so we don't have a ton of time to waste.
Tomorrow's opening bell will be on us before you know it, and I've uncovered a new Nasdaq Biotech profile with tremendous upside potential based on several key factors.
For one, this is a low float profile with tons of major 2022 news already under its belt since the turn of the year.
And operating with the explicit desire to carve out a chunk of a market that could be worth upwards of $100Bn by 2026, this profile could start turning heads in the years to come.
But before that happens, don't you think you may want to have it on your radar while it trades under $1.00 per share (as of close Tuesday)?
At 9:30AM EST Wednesday, the full report arrives.
Here's a few tasty tidbits to chew on ahead of time.
Top 3 Potential Catalysts - Important Must-Know Details On Your New Nasdaq Profile
#1. Mentioned above, this is a low float profile which means the potential of volatility on a daily basis cannot be underestimated. Yahoo Finance reports this profile to have fewer than 15Mn shares in its float.
#2. This month, the company received some positive news involving an important trial for one of their products. If positive news continues to grow, it could become a game-changer for this profile.
#3. A handful of big distribution agreements already in 2022 could signal this company is all in and may not fly under Wall Street's radar for much longer.
Since you've got a minute now, do this: